#South Korea #Seoul #biotech #ImmunoForge #TIPS Program

ImmunoForge Selected for 'Global TIPS R&D' Program

ImmunoForge, a South Korean biotech company focusing on the development of treatments for rare diseases, has recently been honored with selection for the prestigious Global TIPS R&D program. Co-led by CEOs Sung-Min Ahn and Ki-Ho Chang, the firm is set to receive KRW 5 billion in government funding over the next four years. This initiative is organized by the Ministry of Small and Medium Enterprises and Startups (MSS) and the Korea Technology and Information Promotion Agency for SMEs (TIPA).

Selection Process and Funding

The Global TIPS R&D program targets promising companies within the biotechnology and healthcare sectors. The selection process involved a rigorous two-stage evaluation; a preliminary written assessment followed by an in-person review. ImmunoForge's innovative approach and solid technological foundation led to its successful selection, marking a crucial milestone in the company's ambition to propel forward.

LMT Platform: A Groundbreaking Approach

One of the major highlights of ImmunoForge's project is the focus on the Leptin receptor-Mediated Transcytosis (LMT) platform. This platform stands out for its potential to penetrate the Blood-Brain Barrier (BBB) effectively, presenting a solution with fewer side effects compared to existing technologies. By combining this with long-acting technology, ImmunoForge aims to create a novel formula that provides one-month sustained drug release, which is particularly valuable for central nervous system (CNS) targeted therapies.

The hybrid platform merges Leptin receptor-mediated activity with lipid nanoparticles (LNPs), signifying a strategic leap designed to enhance drug delivery directly to the CNS. Such innovative techniques are critical in addressing the challenges faced in drug development for CNS disorders, where treatment efficacy is often hampered by the BBB.

Future Development and Global Partnerships

With the support of the government program, ImmunoForge plans to escalate their efforts in developing CNS-targeted therapeutics. The company is keen on establishing collaboration with both domestic and international firms to identify suitable drug candidates that leverage the LNP technology and various modalities, including mRNA and siRNA.

"We are thrilled about the choice our company has received in the Global TIPS RD program and are committed to expanding the LMT platform while fostering partnerships that can yield pioneering drug solutions," remarked Ki-Ho Chang, one of the Co-CEOs.

ImmunoForge’s recent recognition at Novo Nordisk’s Open Innovation contest serves as a testament to its advanced technological competencies on a global level. As the company prepares for extensive development phases, it is confident that its LMT platform and proprietary technologies will position it as a frontline partner in the realm of CNS disorders.

Conclusion

ImmunoForge's selection into the Global TIPS R&D program not only signifies a remarkable step for the company but also reflects South Korea's commitment to fostering innovation in the biotech sector. With a clear roadmap ahead, ImmunoForge is poised for significant contributions to the healthcare landscape, particularly in the development of treatments for rare diseases affecting the central nervous system. This initiative will surely advance the company's mission to provide effective therapeutic solutions and enhance the quality of life for patients around the world.